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Abstract: 
Objectives: This systemic review is conducted to compare between Percutaneous Coronary 
Intervention (PCI) and Coronary Artery Bypass Graft (CABG) in the revascularization strategy 
of patients with diabetes mellitus (DM) and multivessel coronary artery disease (CAD) based on 
clinical outcomes. 
Background: Diabetes mellitus approached epidemic proportions globally and was recognized 
as a risk factor of aggressive and multivessel CAD [1,2]. The controversy over the optimal 
revascularization strategy for patients with DM and multivessel CAD has been hotly debated for 
more than 10 years. Numerous studies and data analysis were conducted to compare between 
PCI and CABG based on clinical outcomes of DM patients after procedure. Those studies 
enormously contributed to the improvement in long-term survival rate, major adverse cardiac 
and cerebrovascular events (MACCE) rate, quality of life, and cost-effectiveness. 
Methods:  This systemic review utilized PubMed, ScienceDirect, and Google Scholar as search 
engines. A total of 39 articles were recruited. Among them, 26 articles were analyzed and 
organized based on timeline, where data about long-term survival rate, the MACCE rate, quality 
of life, complications after both procedures were extracted and conclusions were made. 
Results: In the bare-metal stent era, CABG showed better outcomes compared with PCI for both 
short- and long-term clinical outcomes. Patients who underwent PCI had significantly higher 
mortality rate, MACCE rate, and repeated revascularization rate compared with patients who 
underwent CABG. However, with the advent of drug-eluting stent, PCI became comparable to 
CABG especially in short-term outcomes. Nonetheless, CABG still surpassed PCI in the long 
run with smaller mortality, myocardial infarction (MI) rate, and repeated revascularization risk at 
five-year follow-up. Hence, CABG remains the revascularization strategy of choice for patients 
with DM and multivessel CAD.  
Conclusion: Although patients who underwent CABG face higher risk of stroke compared to 
patients who underwent PCI, CABG outweighs PCI with the reduced mortality, MI rate and 
repeated revascularization rate, especially in long-term follow-up. Supposing the decision 
process depends on clinical judgment and accessibility to procedure, CABG should be preferable 
in patients with DM and multivessel CAD. 
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Percutaneous coronary intervention versus coronary artery bypass graft in the treatment 
of multivessel coronary artery disease on Diabetes Mellitus patients 
Introduction 
The global prevalence of diabetes mellitus (DM) has almost doubled in the past three 
decades, rising from 4.7% in 1980 to 8.5% in 2014. It has been considered a worldwide epidemic 
of the 21st century [1,2]. Since DM patients have 2 to 4-fold increased mortality risk from 
coronary artery disease (CAD), it is a major factor in determining long-term prognosis [3].  
Furthermore, a large percentage of diabetic patients display multivessel CAD due to the systemic 
nature of atherosclerotic process in DM [4]. The connection between diabetes and CAD can be 
justified by the following mechanisms. Firstly, high blood sugar level stimulates the expression 
of glycoprotein IIb/IIIa on the platelets surface, leading to the elevated aggregation [5]. Second, 
several inflammatory factors and adhesion molecules thrive in diabetic patients including C-
reactive protein, tumor necrosis factor, CD40, vascular cell adhesion molecule-1, and 
intercellular adhesion molecule [6]. Finally, many diabetic patients concurrently have metabolic 
disorders and cardiovascular comorbidities such as hyperlipidemia, obesity, hypertension, heart 
failure, etc. Therefore, diabetes accelerates the endothelial dysfunction and the diffuse 
atherosclerosis process leading to a high rate of multivessel CAD or left main coronary disease. 
Despite advances anti-thrombotic drug therapy and revascularization methods, Percutaneous 
coronary intervention (PCI) and Coronary artery bypass graft (CABG) remain the treatment of 
choice for patients with diabetes and multivessel CAD. The long-standing debate over the 
optimal revascularization strategy for patients with diabetes and multivessel CAD has continued 
to be a vibrant discussion topic for more than 10 years.  
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Over the last decade, PCI technique has developed dramatically from bare-mental stents 
to drug-eluting stents and pronouncedly improved patient outcomes. Thus, does CABG still is 
preferred over PCI in revascularization for diabetic patients with multivessel CAD? This paper 
intends to dive deeper into numerous clinical outcomes of diabetic patients with multivessel 
CAD who underwent either PCI or CABG to answer this question.  By guiding patients in the 
decision process of their revascularization method, the importance of this paper is to improve 
clinical outcomes such as mortality rate, MI and stroke rate, cost-effectiveness, quality of life, 
etc.  
Methods: 
By utilizing different research tools such as PubMed, ScienceDirect, and Google Scholar, 
this paper identified numerous studies comparing PCI and CABG in the treatment of multivessel 
CAD on diabetic patients. Keywords that were used in the searching process included 
“Percutaneous coronary intervention”, “Multivessel coronary artery disease”, “Diabetes type II”, 
“Coronary artery bypass graft”, “Comparison”, “Survival rate”, “Cost-effectiveness”, “Quality of 
life”, “Bare-metal stent”, “Drug-eluting stent”. There were three articles that examined bare-
mental stent placement versus CABG, 23 articles specifically analyzed PCI with drug-eluting 
stent versus CABG. All studies were no older than 15 years with the oldest study was published 
in 2005. Most articles were dedicated to diabetic patients with multivessel CAD or at least had a 
subgroup of diabetic patients. In addition, this paper prioritized applying randomized controlled 
studies as its core. The reference lists of those trials were utilized as a systemic review to find 
relevant studies to boost the validity of this meta-analysis (Appendix A).  
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The major inclusion criteria included participants who were older than 18 years old from 
both sexes, pre-existing DMII, angiographically confirmed multivessel CAD [≥70% occlusion in 
≥ 2 major epicardial vessels or in ≥ 2 separate coronary artery including left anterior descending 
(LAD) artery, left circumflex (LCX) artery, and right coronary artery (RCA), eligible candidates 
for both PCI and CABG. The major exclusion criteria included pre-existing congestive heart 
failure (NYHA class III and IV or pulmonary edema), prior CABG surgery, prior cardiac valve 
surgery, prior PCI or previous stroke within six months, history of hematologic disease, 
suspected pregnancy, dementia. The author of this paper carefully reviewed all data and analyzed 
all articles separately. After compare and contrast valuable studies, appropriate data and results 
are extracted to ensure the coherence of this paper. 
Background:  
Percutaneous Coronary Intervention (PCI) is a nonsurgical procedure that is used to treat 
occlusive coronary arteries found in CAD. PCI is combined of two main steps: coronary 
angioplasty and stents placement. After accessing blood stream through peripheral artery, a 
coronary catheterization is used to visualize the coronary arteries and angioplasty is performed 
with a balloon catheter. The inflated balloon recaptures the occlusive coronary artery and a stent 
is placed to keep the vessel open. According to ACC/AHA guidelines released in 2001, the 
indications of PCI are diverse, varies from acute coronary syndrome to stable CAD [7]. Some of 
the indications include acute ST- elevation myocardial infarction, non ST- elevation acute 
coronary syndrome, left main coronary artery disease or left anterior descending disease, chronic 
total occlusion, angina (stable and unstable), high risk surgical patients, positive stress test, and 
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DMII with multivessel CAD. Therefore, PCI is widely applied now for patients with CAD, 
varies from asymptomatic to moderately and severely symptomatic ones.  
Stent in PCI is defined as a wire-meshed tube that keeps the vessel open. Stent can be 
either drug-eluted or bare-metal. According to the book Essentials of Cardiac Anesthesia for 
Noncardiac surgery of Emilio B. Lobato [8], bare-metal stents, which is the first stent using in 
coronary stenting could be made from stainless steel, cobalt chromium, or platinum chromium. 
First brought to the clinic in the 1990s, bare-metal stent successfully diminished the incidence of 
the two most common periprocedural complications of coronary arteries revascularization 
including restenosis and acute vessel closure, compared to balloon angioplasty. Hence, according 
to Fischman et al.,[9] patients who underwent bare-mental stenting had higher successful 
procedure rate and lower rate of restenosis than patients who underwent balloon angioplasty 
(96.1% vs. 89.6% and 31.6% vs. 42.1%, respectively). The introduction of drug-eluting stents 
into practice became a millstone of PCI technique evolution and contributed enormously to the 
broad applications of this procedure in contemporary medicine. The stent slowly releases 
antiproliferative agents such as paclitaxel and “limus” family. According to A randomized 
comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization 
conducted by Morice et al.,[10] restenosis (50% or more of the luminal diameter) did not occur 
on any sirolimus-stent patients participated in the study at six months after procedure. However, 
it occurred on 26.6% patients in the bare-metal group. Furthermore, at one year follow-up, the 
bare-metal group had significantly higher rate of major cardiac events compared to sirolimus-
stent group (28.8% vs. 5.8%, respectively). Thus, drug-eluting stent remarkably increase the 
clinical outcomes of PCI procedure by preventing neointimal proliferation.  
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CABG is a surgical procedure, which is also used in CAD treatment by reinstating blood 
flow to the occlusive coronary arteries. The procedure has two main approaches. In the first one, 
left internal thoracic artery is pedicled and rerouted into the left anterior descending coronary 
artery. The second approach uses the great saphenous vein to connect between aorta and the 
obstructed coronary artery. The 1999 ACC/AHA guidelines for CABG surgery listed various 
indications including significant left main coronary artery stenosis (>70%), significant left 
anterior ascending coronary artery stenosis (70%), three-vessel CAD, two-vessel CAD with left 
anterior ascending coronary stenosis, disabling angina despite ultimate noninvasive therapy[11]. 
This procedure is mostly performed to relieve uncontrolled angina, prevent left coronary artery 
dysfunction and death from myocardial infarction (MI).  
Therefore, PCI and CABG share the same indication for diabetic patients with CAD. PCI 
is preferable in patients who required urgent revascularization. However, the choice between PCI 
and CABG on diabetic patients with multivessel CAD, who are belongs to the scope of this 
paper is affected by numerous factors such as the number of occlusive coronary vessels, patients 
comorbidities, the complexity of anatomy of the lesion, etc. Therefore, this topic remains as 
highly debated.  
In the bare-metal stent era, Serryus et al. [12] conducted one of the first randomized trials 
to compare between stent implantation and CABG for multivessel disease, called the Arterial 
Revascularization Therapy Study (ARTS-I trial). Between April 1997 and June 1998, 1205 
diabetic and non-diabetic patients with multivessel CAD were enrolled and randomly assigned to 
undergo either PCI with bare-metal stents or CABG. All patients were suitable candidates for 
both procedures. Personal assessments including patient’s history, questionnaires about angina 
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status, quality of life, hospital cost were performed after 30 days, six months, and 12 months of 
post-procedure period. At 30 days after procedure, patients who underwent stent implantation 
had higher risk of develop an MACCE (26.2%), compared to patients of CABG group (12.2%). 
In fact, the MACCE rate, which was the combination of all-cause mortality, MI rate, stroke rate 
and repeated revascularization, was a crucial endpoint in all of the studies belonging to the scope 
of this paper.  In addition, at 12 moths of post-procedure, 21.0 % of stenting group had to be 
revascularized, only 3.8 % of the CABG group underwent another revascularization procedure 
[8]. Furthermore, more patients from CABG group were relieved from angina, compared to 
stenting group (90% vs. 79%, respectively). Patient used self-assessment EuroQoL questionnaire 
as a tool to evaluate their quality of life. Scores were collected at one month, six months and 12 
months after intervention. A significant better quality of life after PCI compared to CABG was 
noticeable at one month (84±16 vs. 78± 17, respectively); meanwhile, there was no difference 
after 6 months (86±16 in PCI and 86±15 in CABG). Patients in the CABG group experienced 
slight better quality of life at 12 months (87±16 in CABG vs. 86±16in PCI). The cost of initial 
procedure of CABG outpaced that of stent implantation for $4,212 more due to prolonged 
hospitalization. On the other hand, because of the significant higher risk of repeated 
revascularization, there was no important cost-effective disparity between CABG and PCI in the 
long run. 
Clinical and economic impact of diabetes mellitus on percutaneous and surgical 
treatment of multivessel coronary disease patients: insights from the Arterial Revascularization 
Therapy Study (ARTS) trial was conducted by Abizaid et al. [13], to examine the results of the 
ARTS-I trial in the subgroup of diabetic patients, which accounted for 17.3% of total 1205 
participants. The one-year clinical outcomes were noteworthy for the lowest MACCE-free 
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survival rate of diabetic stenting group (63.4%), compared with both diabetic CABG group 
(84.4%) and nondiabetic stenting group (76.2%). This finding demonstrated that diabetes was an 
independent risk factor of 1-year MACCE after PCI procedure but not after CABG. 
Interestingly, there was no critical difference in one-year event-free survival rate between 
diabetic and non-diabetic group of patients who were treated with CABG (84.4% vs. 88.4%, 
respectively). The total one-year cost of treatment in diabetic patients who underwent PCI was 
$12,855 and who underwent CABG was $16,585. In nondiabetic group, one-year treatment cost 
$10,164 for stenting and $ 13,082 for CABG. Therefore, the total one year cost of treatment in 
CABG patients outranged that in PCI patients, regardless of diabetic status. Essentially, in 
diabetic patients, the risk of repeated revascularization of stenting patients doubled that of CABG 
patients (21.6% vs. 12.4%, respectively). This subgroup analysis revealed that CABG provides a 
superior clinical outcomes at one year compared with PCI, especially in diabetic patients with 
multivessel CAD. 
Serryus et al.[14], continued to follow their participants of the ARTS-I trial and collected 
various data in five years. Authors published a data analysis named Five-year outcomes after 
coronary stenting versus bypass surgery for the treatment of multivessel disease: the final 
analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial in 2005. 
Among 208 diabetic patients, the mortality rate of those who were treated with stent implantation 
was 13.8%, versus 8.3% in those who underwent CABG [10]. Diabetes was critically relevant to 
risk of death within stenting group (13.4% death in diabetic group and 6.8% death in non-
diabetic group) [10]. In contrast, there was no significant difference in 5-year mortality between 
diabetic and non-diabetic group that both underwent CABG (8.3% vs. 7.5, respectively). 
Furthermore, in stenting group, diabetic patients had higher rate of MACCE at 5 years of post-
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procedure than non-diabetic patients (54.5% vs. 38.7%, respectively) [10]. The rate of MACCE 
at 5 years of diabetic group underwent CABG was similar with that of non-diabetic group 
(25.0% vs. 21.2%, respectively). Although patients who chose CABG as their treatment were 
older and had more co-comorbidity, their clinical outcomes continuously improved and became 
better than that of PCI patients. Therefore, Serryus et al.[14], concluded that CABG remained as 
a procedure of choice of revascularization on multivessel CAD, especially in diabetic patients. 
After publishing the ARTS-I, Serryus et al.[15], began work on ARTS-II, the first 
multicenter, non-randomized, stratified study comparing between drug-eluting stent implantation 
vs. CABG on multivessel CAD. By using the surgical group of patients from the ARTS-I as 
historical control, new patients with similar inclusion criteria were recruited and underwent PCI 
with sirolimus-eluting stents. 607 patients of this ARTS-II arm were stratified to ensure that the 
huge part of them had diabetes (26.2%) and multivessel CAD (53.5%). Clinical outcomes were 
examined at 30 days and at one year after procedure and following data were drawn out. The 
incidence of death and MACCE in ARTS-II population at 30 days was lower than that in ARTS-
I population (ARTS-I- CABG 5.5%, and ARTS-I-PCI 5.2%). There was no significant difference 
in the one-year MACCE rate between ARTS-II population and ARTS-I-CABG (10.5% vs. 
11.7%, respectively) [11]. However, ARTS-II patients still faced higher risk of repeated 
revascularization, compared to the ARTS-I-CABG patients (8.5% vs. 4.2%, respectively) [11]. 
By revealing how sirolimus-eluting stents reduced the death and MACCE rate compared to bare-
mental stenting, this study affirmed that PCI with drug-eluting stents had its efficacy and safety 
in treatment of multivessel CAD patients.  
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To investigate on the specific impact of the ARTS-II on diabetic patients, Macaya et 
al.[16], conducted an analysis called One-year results of coronary revascularization in diabetic 
patients with multivessel coronary artery disease. Sirolimus stent vs. coronary artery bypass 
surgery and bare metal stent: insights from ARTS-II and ARTS-I based on its data and results. 
The authors divided the ARTS-I and ARTS-II population into two groups of diabetic (367) and 
non-diabetic patients (1445). They acknowledged two crucial outcomes. First, diabetics of the 
ARTS-II trial demonstrated a comparable one-year MACCE rate with diabetics of the ARTS-I-
CABG trial (15.7% vs. 14.6%, respectively) regardless their increased complexity in CAD. 
However, cerebrovascular events occurred more frequently in ARTS-I-CABG diabetics (5.2%) 
than in ARTS-II diabetics (0%). As expected, the one year MACCE rate in ARTS-II diabetics 
was significantly lower than that in ARTS-I-PCI diabetics (15.7% vs. 36.6%, respectively). 
Second, in the ARTS-II population, diabetics surpassed non-diabetics in overall MACCE rate, 
incidence of death, need for repeat revascularization (15.7% vs. 8.5%, 2.5% vs. 0.4%, and 12.5% 
vs. 5.6%, respectively). This study depicted the phenomenal antirestenotic effect of sirolimus-
eluting stent through improvement in early outcomes, especially in diabetic patients. 
Interestingly, CABG remains a preferable method of choice to prevent repeated 
revascularization. Diabetes mellitus continue being defined as an independent risk factor for 
MACCE after coronary revascularization. This sub-analysis of the main ARTS-I and ARTS-II 
trials did not have large enough number of patients to provide a sufficient power. Another 
potential bias could be attributed to long-term follow-up, in which clinical outcomes were 
strongly affected by the improvement of medicine and technology. In addition, the differences 
between the current ARTS-II population and the historical ARTS-I population required statistical 
adjustment to avoid non-randomized study bias. 
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Daemen et al.[17], continued to follow-up participants of the ARTS-II trial for 3 years 
and specifically assigned them into diabetic and non-diabetic groups. In the non-diabetic group, 
the MACCE in ARTS-II patients showed no distinct differences with ARTS-I-CABG patients 
(16.3% vs. 15.8%, respectively), but was significantly lower than ARTS-I-PCI patients (16.3%vs 
30.9%, respectively). The MACCE rate at 3-years in non-diabetic patients participated in the 
ARTS-I and the ARTS-II trials experienced similar trends. Furthermore, the combined rate of 
death from all-cause, nonfatal MI and nonfatal stroke in non-diabetic ARTS-II was significantly 
lower than both non-diabetic ARTS-I-CABG and ARTS-I-PCI (7.8%, 10.3%, and 11.5%, 
respectively). In the diabetic group, the MACCE rate of ARTS-II patients outstripped that of 
ARTS-I-CABG (27.7% vs. 17.7%, respectively), but was not as high as that of ARTS-I-PCI 
(27.7% vs. 47.3%, respectively). The combination of death from all-causes, nonfatal MI and 
nonfatal stroke in ARTS-II patients remained slightly higher than all ARTS-I patients.  
Another important trial conducted by Ong et al.[18], was a prospective, multicenter, 
multinational randomized study called the SYNergy between percutaneous coronary intervention 
with TAXus and cardiac surgery (SYNTAX) study. A total of 1800 patients who were 
angiographically confirmed of de novo triple-vessels disease or left main disease were recruited 
and randomly assigned to undergo either PCI with TAXUS Express paclitaxel-eluting stents or 
CABG. Mack et al. [19], conducted a three-year follow-up of the SYNTAX trial called Bypass 
versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic 
syndrome, aiming patients with diabetes mellitus or metabolic syndrome. The MACCE rate of 
PCI patients remarkably exceeded that of CABG patients, regardless the presence of diabetes. 
This trend was also witnessed in the main endpoint of death/MI/stroke and in the risk of repeated 
revascularization. However, diabetes recognized as a remarkable risk factor that significantly 
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elevated the MACCE rate, mortality, and repeated revascularization risk for PCI arm, compared 
with the CABG arm. For instant, in PCI group, the MACCE rate of diabetic patients accounted 
for 37.0%, which was remarkably higher than that of non-diabetic patients. Meanwhile, in 
CABG group, the MACCE rate of diabetic solely was slightly higher than that of non-diabetic 
patients (p=0.264). The SYNTAX study has limitations since its primary endpoint was not met 
due to the lost of participants. Therefore, the result of this subgroup analysis solely had 
observational and hypothesis generating meaning. 
Diabetic and Nondiabetic Patients with Left Main and/or 3-vessel Coronary Artery 
Disease conducted by Banning et al.[20], was another comparison of the SYNTAX trial’s 
outcomes on diabetic vs. non-diabetic group at one-year follow-up. In diabetic patients, the one-
year MACCE rate pronouncedly elevated after PCI treatment compared with CABG treatment 
(26.0% vs. 14.2%, respectively). In non-diabetic patients, the 1-year MACCE rate was slightly 
but not significantly higher in the PCI group compared with the CABG group (15.1% vs. 11.8%, 
respectively). The combined of mortality, MI, and stroke rate was similar between CABG group 
and PCI group despite diabetes status of patients. In regard to death rate, diabetic group always 
exceeded non-diabetic group after either treatments. In addition, risk of stroke in CABG group 
significantly higher than PCI group regardless diabetes status of patients. Risk of repeated 
revascularization displayed an opposite trend where PCI group always surpassed CABG group in 
both diabetic and non-diabetic patients. The study had several significant limitations. First, one 
year follow-up could not reflect completely the difference between CABG and PCI treatment. 
Second, because of the small sample size of the subgroups, all the results of this analysis are 
solely intended to be observational and hypothesis generating. Third, diabetic status of patients 
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was confirmed at the beginning of the study; subsequent diagnosis of diabetes during the course 
of the study was not recorded.  
Kappetein et al.[21], conducted a five-year follow-up of the SYNTAX trial, dedicated 
solely for diabetic participants. Through classification of patients by their diabetes status, the 
study successfully came up with remarkable results. In both diabetic and non-diabetic groups, the 
MACCE rate after PCI always exceeded CABG (46.5% vs. 29.0%, 34.1% vs. 26.3%, 
respectively). The combined rate of death from all-causes, nonfatal MI, and nonfatal stroke in 
diabetic group and non-diabetic group are similar. There was an increased repeat 
revascularization risk occurred among PCI patients, compared with CABG patients in both 
diabetics (HR=2.75, 95%CI, 1.78-4.24) and non-diabetics (HR=1.82, 95% CI, 1.39-2.38). 
Therefore, the difference in clinical outcomes between PCI and CABG was more noticeable in 
diabetic group, compared with non-diabetic group. Patients who underwent CABG shared 
similar outcome despite their diabetic status. In contrast, diabetic patients who underwent PCI 
had pronouncedly worse clinical outcomes than non-diabetic patients with same procedure. In 
this study, the diabetic subgroup was randomly stratified and equally distributed into CABG and 
PCI group. The small sample size did not ensure adequate power of this subgroup analysis and 
therefore, the result could only be viewed as hypothesis generating.  
The CARDia trial by Kapur et al. [22], conducted the first trial to compare between PCI 
and CABG specifically on patients with diabetes and multivessel CAD called the CARDia 
(Coronary Artery Revascularization in Diabetes) trial. The hypothesis of the study was that PCI 
could overcome CABG to become the optimal revascularization strategy for diabetic patients. A 
total of 600 diabetics were recruited and randomly assigned into to group to undergo either PCI 
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or CABG. Data were collected and analyzed at 30 days, six month, one year, two year, and five 
year. Primary endpoint was the sum of death from all-cause, MI, and stroke rate at one year, 
which was estimated about 9% on the PCI arm and about 12.5% on the CABG arm [18]. Using 
PASS 2000 software and a sample size of 300 patients for each control (CABG) and 
experimental (PCI) groups, the study achieved 80% power at a 5% significance level.  
At one-year follow-up, Kapur et al.[23], detected that the combined rate of death, MI and 
stroke in the PCI exceeded that in the CABG group (13.0% vs. 10.5%, respectively) [19]. 
Critically, patients underwent PCI confronted much higher chance to repeat a revascularization, 
compared to CABG patients (11.8% vs. 2.0%, respectively) [19]. In the subgroup of triple-vessel 
disease (60% of all patients), the combination of death from all-cause, nonfatal MI and nonfatal 
stroke transpired in 15.2% of PCI patients vs. in 11.0% of CABG patients [19]. Meanwhile, the 
subgroup of two-vessel disease experienced a contrast trend (9.8% in CABG patients vs. 8.9% in 
PCI patients). The trend of stroke rate still favored PCI (0.4%) compared with CABG (2.8%).  
The study utilized the Canadian Cardiovascular Society to examine the angina pectoris relief on 
participants. Patients in CABG group were less likely to have angina and the trend was observed 
in all CCS class of angina (p<0.001). Although PCI cannot beat CABG in the revascularization 
of diabetic patients even with the drug-eluting stent, it showed no inferior compared to CABG in 
1-year endpoints. The CARDia trial is the first prospective randomized trial to compare between 
PCI and CABG on diabetic patients. Hence, although the study was terminated early due to the 
withdrawal of participants, the result of CARDia significantly contributed for this paper. Long-
term follow-up is required to provide a definitive answer for this long-established debate. 
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Farkouh et al.[24], conducted a multicenter randomized trial called The Future 
revascularization Evaluation in patients with Diabetes mellitus: Optimal management of 
Multivessel disease (FREEDOM) Trial to determine the exceptional approach for 
revascularization in patients with DM. From 2005 to 2010, 1900 DM, angiographically 
confirmed with multivessel CAD patients were enrolled and divided into two groups of either 
CABG or PCI using drug-eluting stent (DES). Patients were scrutinized for 30 days, one year 
and annually up to five years. The study had two significant outcomes. The primary outcome 
was the combination of death from any cause, nonfatal MI and nonfatal stroke at five year of 
follow-up [20]. The second outcome appraised the rate of MACCE at one-year of post 
randomization. Other outcomes measured rate of death for all-cause including cardiovascular 
mortality at one, two, and three year of post-randomization, quality of life at 30 days, one and 
three year follow-up, cost-effectiveness. This trial found that all-cause mortality at five years was 
2.66% and 18.7% in the CABG group and in the PCI group, respectively. This absolute 
difference of 7.9 percentage points (95% CI, 3.3 to 12.5) demonstrated the superiority of CABG. 
In addition, the benefit of CABG was illustrated by the decreased rate of MI at five years 
(p<0.01). However, the five years percentage of stroke of CABG group (52%) surpassed that of 
PCI group (22%) (p=0.03) [20]. Moreover, the study recognized a disparity in the rates of 
MACCE at one year after the procedure between CABG group (11.8%) and PCI group (16.8%) 
(p=0.004) [21]. The study had two compelling limitations. First, because of the limited 
prevalence of subgroups, the statistical power was not sufficient to detect the interactions 
between subgroups. Second, the trial was not blinded, and patients could receive different 
method of treatments during long-term follow-up period. Despite those potential biases, the long 
duration of patient’s follow-up with the median of 3.8 years, the objective adjudication of the 
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outcomes, the variability of participants’ background strengthened this important study. The 
result of this trial was a reflection of real-life practice and can be wildly applied in diabetic 
patients with multivessel CAD. 
Farkouh et al. [25], continued their work by conduct a follow-up study of their 
FREEDOM trial, centralizing on the long-term survival rate of patients with DM after mutivessel 
revascularization. They successfully persuade enrolling centers and patients from their previous 
FREEDOM trial to engage in this follow-up study with median of 7.5 years. According to Long-
Term Survival Following Multivessel Revascularization in Patients with Diabetes: The 
FREEDOM Follow-On Study, of total 314 deaths during the entire study, the all-cause mortality 
rate in PCI group outweighed that of CABG group (24.3% vs. 18.3%, respectively). 
Furthermore, statistical analysis illustrated a significant decrease in numbers of MI (eight events 
versus ten events) and stroke (three events versus five events) in the CABG group comparing to 
the PCI group. These results endorse that CABG should be the preferable revascularization 
strategy for DM patients. Although this extended follow-up only recruited 49.6% of the original 
population of the FREEDOM trial, it did not create significant differences between cohorts with 
or without extended follow-up. Therefore, the loss of initially enrolled patients did not greatly 
affect long-term survival. After the FREEDOM trial, multiple new generations of stents have 
been introduced into practice and the results of this trial were limited in interpreting this fact. 
Meanwhile, the change in PCI platforms did not greatly influence the advantage of CABG over 
PCI in long-term survival rate. 
Although the FREEDOM trial provided robust evidence of using CABG over PCI in 
multivessel revascularization of DM patients, Tam et al.[26], found the need to examine this 
result and its application on a larger scale. From October 2008 to December 2018, a retrospective 
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analysis named Long-Term Survival After Surgical or Percutaneous Revascularization in 
Patients With Diabetes and Multivessel Coronary Disease recruited 14,235 diabetic and 
angiographically confirmed of two-vessel or three-vessel CAD patients, in which 4,519 patients 
underwent PCI and 9,716 patients were treated with CABG. Data analysis displayed that PCI 
were significantly younger, more likely female, and had less severe CAD. Propensity score 
matching, which relied on 23 baseline covariates including age, sex, race, pulmonary and renal 
disease, cardiac comorbidities, NYHA classification, socioeconomic status, etc., generated 4,301 
patients-pairs. Critically, the study reported no meaningful divergence in early deaths between 
PCI group (2.4%) and CABG group (2.3%) (Absolute risk difference [ARD]=0.12, p=0.721) 
[23]. At eight year follow-up, all cause of mortality of PCI acquired 27.0%, which outstripped 
that of CABG group with solely 19.4% (Hazard ratio [HR]: 1.39). The study accessed 
independently the components of MACCE and was able to achieve multiple important results. It 
was noticeable that the incidence proportion of MI accounted for 7.2% after CABG compared 
with 16.4% in the PCI group (HR: 2.32). The chance to repeat revascularization tripled for 
patients undergoing PCI (HR: 3.65). Crucially, although the findings of this study were 
consistent with that of the FREEDOM trial, Tam et al., were capable to approach patients with 
left main disease. In addition, the heart of the study is to utilize the propensity score matching to 
establish more balanced groups and to eliminate any potential bias. In conclusion, this study 
reinforced that CABG is a better surgical procedure for multivessel CAD in diabetic patients.  
The FREEDOM trial is the largest trial to compare PCI and CABG in revascularization 
of patient with diabetes and multivessel CAD, which screened a total of 32,966 patients for 
eligibility. The study also used contemporary techniques and optimal post-procedure medicine 
treatment, compared with previous studies. However, Bansilal et al. [27], inspected the typical 
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features of the subjects participated in the FREEDOM trial and launched a comparison with 
other trials with similar targeted patients to verify its reliability. According to The Future 
REvascularization Evaluation in patients with Diabetes mellitus: optimal management of 
Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry, the 
mean age of this randomized cohort was 63.1±9.1 years old and 29% of enrolled subjects were 
female. The majority of them (83%) had angiographic three-vessel CAD with median diabetes 
duration of 10.2±8.9 years. Almost all of them have hypertension (mean systolic blood pressure= 
133.7±19.8 mmHg) and hyperlipidemia (mean LDL= 92.7±36.3 mg/dl). A large percentage of 
participants had tobacco exposure (55%) and obesity (42%).  The mean HbA1C of the study was 
78±1.7 mg/dl with 32% of recruited patients being prescribed insulin therapy. These clinical and 
angiographic traits of participants of the FREEDOM trial were comparable to those from other 
studies including Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2-D), 
Coronary Artery Revascularization in Diabetes (CARDia), SYNTAX, BARI, etc. Therefore, 
authors concluded that the FREEDOM trial was adequate to provide a precise answer to the 
long-term debate on the optimal revascularization strategy for patients by dedicating to high-risk 
diabetic patients only. 
Magnuson et al.[28], weighted up the cost effectiveness of PCI vs. CABG in patients 
with diabetes and multivessel CAD by conducting a study, which analyzed results from 
FREEDOM trial. In-person evaluations were administered at one month, six months, and 12 
months of post-procedure and annually up to five years to estimate the medical care cost of 1900 
patients participated in the FREEDOM trial. Cost-effectiveness of percutaneous coronary 
intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus 
and multivessel coronary artery disease: results from the FREEDOM trial determined two 
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exclusive outcomes.  Although PCI has a higher initial procedure cost due to exorbitant price of 
stents and other devices, the primary outcome revealed that the total cost for the index 
hospitalizations for CABG exceeded that for PCI, which was attributed mostly to longer hospital 
stay and physician cost. Secondly, CABG remains the exceptionally cost-effective 
revascularization strategy for patients with DM and multivessel CAD by reason of following 
factors. After the first five years of post-procedure, CABG profitably reduced follow-up costs up 
to $1,672/year (95% CI, $942 to $2,403). Further, a rise in quality-adjusted life expectancy of 
0.663 QALYs (95% CI, 0.177 to 1.132) was detected in the study. Finally, CABG extended life 
expectancy with an average of 0.794 years with a distinguished gain in incremental cost-
effectiveness ratios of $6,791/life year .  
Although the FREEDOM trial strongly demonstrated the superiority of CABG in terms 
of long-term survival rate and risk of MACCE, Abdallah et al.[29], felt the necessity for evaluate 
the health status from the patient’s point of view.  The baseline health status of 1880 patients 
from the FREEDOM trial was examined with following factors: angina frequency (AF), physical 
limitations (PL), and quality of life (QOL) domains of the Seattle Angina Questionnaire (SAQ). 
Patients would rate each factors by utilizing a scale from zero to 100 points. SAQ-AF of CABG 
group at one year and two years follow-up was marginally higher than that of PCI group (mean 
difference 1.0 and 1.3 points). However, at three years of post-procedure, there was not 
significant difference in angina alleviation between those two groups. Likewise, the scores for 
PL and QOL subscales at one year follow-up were meaningfully greater in patients undergoing 
CABG, with mean differences 2.0 points and 1.9 points, respectively [26]. In contrast, the study 
found no compelling distinct in SAQ-PL and SAQ-QOL scores between two groups of patients 
after two years of procedure, which suggested that the benefit of CABG in terms of quality of 
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life and health status was not clinically significant. From one month to five years after the 
procedure, both PCI and CABG successfully improved basic health status of patients with 
diabetes and CAD disease, but the comparison did not favor any of these procedures. 
According to Comparative efficacy of coronary artery bypass surgery vs. percutaneous 
coronary intervention in patients with diabetes and multivessel coronary artery disease with or 
without chronic kidney disease, up to 25% of diabetic patients experienced some degree of renal 
impairment [30]. Furthermore, both PCI and CABG contribute risk factors to develop acute 
kidney injury (AKI) on diabetic patients. Arbel et al.[31], conducted an analysis based on results 
from the FREEDOM trial to determine the incidence of AKI on diabetic patients undergoing 
whether PCI or CABG. As a result, 12.3% participants developed AKI after procedure and more 
frequently in CABG group, accounting for 15.6%. Another crucial conclusion of that AKI 
occurring at 5 years of post-procedure associated with higher risk of MACCE (34.6% vs. 20.5%, 
respectively). However, neither CABG nor PCI has a significant relevance with AKI (p=0.89), 
which suggested that the two methods of revascularization have equal risk in causing AKI. 
Quintar et al. [32], developed a personal prediction tool to guide diabetic and multivessel 
CAD to determine their optimal revascularization strategy by using anticipated five-year MACE 
and one-year angina post- PCI and CABG. Individualizing Revascularization Strategy for 
Diabetic Patients with Multivessel Coronary Disease used SAQ to measure five different 
elements of health status in FREEDOM trial’s participants including: angina frequency, angina 
stability, quality of life, physical limitation, and treatment satisfaction. The MACE model 
considered numerous clinical variables such as age, sex, race, obesity, peripheral vascular 
disease, renal impairment, cardiac and pulmonary comorbidities, insulin therapy, etc. and the 
treatment interactions with history of tobacco exposure. Aging, prior MI or cerebrovascular 
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event, insulin therapy, lower LVEF, lower eGFR are the factors contributed to the recurrence of 
MACE. Essentially, patients with history of tobacco exposure who underwent CABG had a 
lower risk of MACE compared with PCI (c-statistic of 0.65). Patients who were female, had 
angina at baseline and lower hemoglobin were more likely to report a MI at one year. Overall, in 
the two predicted models of the study showed that PCI never can beat CABG. Hence, CABG 
proved its supremacy for MACE, especially in smoking patients (100%). 
Integrating the Synergy between percutaneous coronary intervention with Taxus and 
Cardiac Surgery (SYNTAX) score into practice: use, pitfalls, and new directions conceded the 
validity of SYNTAX score in pinpointing high-risk patients and guiding the decision process 
between CABG and PCI on each patient [33]. Esper et al.[34], conducted an analysis based on 
the FREEDOM trial, aiming to assess the utility of SYNTAX score on patients with diabetes and 
multivessel CAD. SYNTAX score in patients with Diabetes undergoing coronary 
revascularization in the FREEDOM trial retrospectively calculated the SYNTAX of each 
participant of the FREEDOM trial and release remarkable conclusions. Despite having a low, 
intermediate or high SYNTAX score, PCI patients always have higher incidence of MACCE 
compared with CABG patients (low SYNTAX score: 36.6% vs. 25.9%; intermediate SYNTAX 
score: 43.9% vs. 26.8%; high SYNTAX score: 48.7% vs. 29.7%) [31]. In patients with 
intermediate SYNTAX score, PCI group had higher incidence rate of death from all-causes, 
nonfatal MI, and nonfatal stroke than CABG group (27.2% vs. 17.7%) [31]. There were not 
similar trends observed in the low and high SYNTAX score group. SYNTAX score was 
confirmed as an independent risk factor for MACCE and incidence rate of death from all-causes 
only on PCI group. Therefore, SYNTAX score should not be adopted as a tool for the choice of 
revascularization strategy on patients with diabetes and multivessel CAD. 
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Aggarwal et al.[35], emphasized the dominance of the FREEDOM trial in the long-term 
debate over the most advantageous revascularization for diabetic patients with multivessel CAD 
by comparing it with previous studies with similar research question. The study used the ARTS 
trial and the ERACI II trial as studies of PCI with bare-mental stents vs. CABG to compare with 
the FREEDOM trial. The downside of these former studies was the lack of glycoprotein IIb/IIIa 
inhibitors in PCI to reduce the mortality rate. Additionally, bare-metal stents associated with an 
elevated rate of restenosis, compared with drug-eluting stents used in the FREEDOM trial. Being 
the first trial to compared PCI-DES and CABG, the ARTS II had its limitations of a non-
randomized trial in which surgeons can chose patients for PCI-DES. The selection bias became 
the main cause why the FREEDOM trial surpassed ARTS II. SYNTAX successfully randomly 
recruits two groups of diabetic and multivessel patients who have been revascularized by either 
CABG or PCI-DES. On the other hand, SYNTAX solely examined the MACCE rate, which is 
significant higher in PCI-DES group, while disregarding the survival rate. Both CARDIa trial 
(Coronary Artery Revascularization in Diabetes) and VA-CARDS (Veteran Affairs Coronary 
Artery Revascularization in Diabetes) were terminated early due to the loss of initial enrollment. 
Overall, the FREEDOM trial is a millstone trial contributes significantly to the research of 
revascularization method on diabetic patient. As its results, CABG was confirmed as the 
preferable procedure since it bypasses all vulnerable plaques and fix heavy calcification. 
Several previous studies suggested that CABG was associated with higher risk of post- 
procedure stroke, compared with PCI. Head et al.[36], conducted an analysis of 11 randomized 
trials to evaluate the post-procedure and post-randomization stroke rate and its impact on 
mortality rate. In total of 11,518 patients participated in those 11 trials, 5,522 patients were 
PCI versus CABG in DM patients 25
treated with CABG whereas 5,843 patients underwent PCI. The cumulative stroke rate at 5-years 
follow-up of CABG group exceeded that of PCI group (3.2% vs. 2.6%, respectively). The rate of 
stroke at 30 days showed similar trend when stroke occurred in 0.4% patients randomized to PCI 
and in 1.1% patients randomized to CABG (HR 0.33). Interestingly, non-diabetic patients who 
underwent CABG had lower rate of stroke at 5-year compared with non-diabetic PCI patients 
(2.4% vs. 2.6%, respectively). Meanwhile, the rate of stroke at 5-year of diabetic patients was 
significantly higher in CABG group vs. PCI group (4.9% vs. 2.6%, respectively). The study 
confirmed that diabetes should be considered as a risk factor of stroke in CABG arm. Stroke 
occurrence remarkably impacted mortality rate. For instance, patients who experienced stroke in 
30 days of post-procedure had significant higher mortality rate, compared with patients who have 
not, despite their revascularization strategy. In CABG group, stroke patients had 41.5% mortality 
rate, compared with 8.9% in non-stroke patients. Similarly, in PCI group, stroke patients had 
45.7% mortality rate and non-stroke patients had 11.1%. According to Head et al.[36], rate of 
stroke should be included in the decision progress on the optimal revascularization strategy for 
patients. 
All previous studies mentioned in this paper recruited diabetic patients despite their type. 
Nyström et al.[37], conducted an observational cohort study to compare PCI vs. CABG 
specifically on patients with DM type I and multivessel CAD. From 1995 to 2013, a total of 683 
DMI patients who underwent CABG and 1,863 DM type I patients who underwent PCI were 
recruited and observed during a mean period of 10.6 years. The mortality rate of CABG group 
was 53.3%, exceeded that of PCI group, which accounted for 44.6%. Meanwhile, at one-year 
follow-up, the absolute risk of death in patients who underwent PCI (5.0%) was significantly 
higher than that in patients who underwent CABG (0.7%). The similar trend was observed at two 
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years (8.3% in PCI group vs.1.2% in CABG group) and at 5 years (18.6% in PCI group vs. 6.4% 
in CABG group). Cause of death in PCI patients was more likely attributed to coronary heart 
diseases (HR 1.45, 95%CI, 1.21-1.74). In terms of the adjusted risk for and the frequency of 
repeated revascularization, PCI group always beat CABG group through years of observation 
(20.1/100 person-years vs. 1.9/100 person-years, respectively). The rate and adjusted risk of 
myocardial infarction displayed identical trend (4.6/100 person-years vs. 2.7/100 person-years, 
respectively). At 30 days of post-procedure, the rate of stroke in CABG patients surmounted that 
in PCI patients (1.9% vs. 0.8%, respectively). On the other hand, long-term adjusted risk of 
stroke did not reveal any significant difference between those two groups. 
Discussion: 
Diabetes mellitus (DM) is considered as a sturdy independent risk factor for multivessel 
CAD due to the combinations of several pathophysiology including prothrombotic and 
proinflammatory states, endothelial dysfunction, and metabolic disorders. When it comes to 
revascularization strategy on this specific group, only two treatment methods were 
acknowledged: CABG and PCI. The evolution of stent technology has undeniably improved the 
clinical outcomes of patients underwent PCI. The goal of this paper is to examine whether PCI 
has successfully displayed non-inferiority to CABG in the treatment of diabetic and multivessel 
CAD patients.  
The ARTS-I trial and its follow-up analysis studies compared PCI with bare-metal stents 
vs. CABG based on short- and long-term clinical outcomes such as the MACCE rate, the 
combined death/MI/stroke rate, and the risk of repeated revascularization. CABG was shown to 
be superior compared to bare-metal stenting in every endpoint of the trial. The study also 
identified DM as an independent risk factor for restenosis and repeated revascularization of the 
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PCI arm. This is the oldest study that was included in this paper. As the modern DES evolve and 
reduced cost becomes the only reason to choose bare-metal stents over DES, the ARTS-I trial 
contributes historically to the topic. 
The ARTS-II trial and its follow-up analysis studies demonstrated the contribution of 
DES-PCI to clinical outcomes, especially the short-term ones. DES-PCI was marginally 
comparable to CABG in the MACCE rate and combined death/MI/stroke rate at one year and 
three year follow-up. However, CABG surpassed PCI in every clinical outcome at five years 
follow-up, except for stroke rate. Again, the diabetic subgroup had significant high repeated 
revascularization risk compared with the non-diabetic group. Although the ARTS-II cannot 
prove that PCI-DES is superior to CABG in the treatment of multivessel CAD on DM patients, 
this study remains a millstone in interventional cardiology. Hence, the study successfully 
demonstrated that the use of DES significantly improved the clinical outcomes, compared with 
the bare-metal stents. Therefore, PCI-DES is a safe and efficacious choice for DM patients with 
multivessel CAD. Being a non-randomized study and using the ARTS-I population as historical 
control, statistical adjustments needs to be performed properly to eliminate potential biases and 
ensure the power of the ART-II trial. Therefore, the debate over the optimal revascularization 
strategy for DM patients with multivessel CAD still needs further investigations. 
The SYNTAX trial was the first randomized trial, which compared DES-PCI and CABG 
on multivessel CAD patients. This trial strengthened the benefit of DES on both short- and long-
term clinical outcomes. At one year and five year follow-up, PCI group had similar combined 
rate of death/MI/stroke compared to CABG group despite diabetic status. In contrast, PCI 
showed inferiority to CABG regarding elevated MACCE rate and repeated revascularization 
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risk. The primary endpoint of the SYNTAX trial cannot meet because the lack of enrollment. 
Therefore, its results only have observational and “hypothesis-generating” meaning. 
The CARDia trial was the first comparison study between DES-PCI and CABG targeting 
patients with DM and multivessel CAD. The hypothesis of the study was that PCI-DES is 
noninferior to CABG, especially on the treatment of those specific patients. However, the results 
of the study failed to support this hypothesis and CABG remains superior to DES-PCI in the 
revascularization of multivessel CAD on DM patients. Because long-term follow-up study on 
this trial cannot be conducted due to the loss of initial enrollment, the results of this trial solely 
have observational and “hypothesis-generating” meaning. 
The FREEDOM trial was the largest multicenter, randomized trial that was conducted to 
compare between DES-PCI and CABG in diabetic and multivessel CAD patients. The results of 
the trial and its follow-up studies affirmed that CABG remains the optimal revascularization for 
this specific patient population. CABG group had pronouncedly lower combined death/MI/stroke 
rate at five years follow-up and lower MACCE rate at one year follow-up, compared with PCI 
group. In the long run, CABG was more cost-beneficial despite its extravagant initial cost. 
CABG and PCI shared similar risk of development of AKI after procedure. Furthermore, chronic 
kidney disease did not have great impact on the MACCE rate regardless revascularization 
method. One significant drawback of CABG is the soaring stroke rate post-procedure. Both rate 
of stroke at 30 days and cumulative rate at five years follow-up of CABG group exceeded that of 
PCI group.  
The credibility and validity of the FREEDOM trial has ensured a certain answer 
regarding the optimal revascularization strategy for patients with diabetes and multivessel CAD. 
However, in the real world practice, the implication of the FREEDOM trials showed some 
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limitations. For example, according to Management of acute coronary syndromes in patients 
with diabetes: implications of the FREEDOM trial, only 30% participants of the FREEDOM trial 
had acute coronary syndrome (ACS) while 70% patients with ACS received PCI at all the 
Australian catheterization laboratories. Moreover, the exclusion criteria of the trial included 
patients who experienced STEMI, elevated creatinine kinase and/or CM-MB 72 hours before 
randomization. Therefore, future research should target the emergent reperfusion strategy for 
STEMI on patients with diabetes and multivessel CAD. Another noticeable point is that modern 
antiplatelet agents such as prasugrel or ticagrelor were not yet introduced in the FREEDOM trial. 
According to Prasugrel versus clopidogrel in patients with acute coronary syndromes, prasugrel 
had reduced stent thrombosis by 52%, compared to clopidogrel, especially on DM patients [39]. 
Furthermore, as the interventional cardiology evolves, newer generation of DES has been 
introduced into practice including the new Resolute Integrity Zotarolimus-eluting stent, which 
was approved specifically for the use on DM patients. Those inventions can significantly 
interfere with the implications of FREEDOM trials in real-life practice. Hence, although CABG 
appears to be the treatment of choice for DM patients with multivessel CAD, further 




 Abundant randomized trials and follow-up analysis were conducted to detect the 
definitive answer for the debate on whether PCI or CABG is the optimal revascularization 
strategy for patients with DM and multivessel CAD. By aggregating valid and legitimate data 
from those articles, this review aimed to examine the short- and long- term clinical outcomes 
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after either procedure. The scope of review mostly evaluated of the mortality rate from all-cause, 
nonfatal MI and stroke rate, the MACCE rate, and the repeated revascularization risk, which 
were collected at various points of post-procedure and post-randomization. In the bare-mental 
area, the ARTS-I trial and other follow-up analysis demonstrated that CABG beat PCI in all 
short- and long-term clinical outcomes. Other analysis that targeted the diabetic subgroup of the 
ARTS-I confirmed that diabetes is an independent risk factor to increase the MACCE rate in PCI 
patients. When DES was applied broadly, the ARTS-II and SYNTax trials, proved that PCI was 
merely marginal to CABG in terms of early clinical outcomes, especially the mortality and the 
MACCE rate. However, other analysis revealed that diabetes status contributed to the elevated 
mortality rate and MACCE rate in PCI group. The CARDia trial and the FREEDOM trial, which 
targeted solely diabetic patients with multivessel CAD, concluded that CABG remains the 
optimal revascularization for this specific group of patients. 
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